The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: Focus on Severe Cutaneous Adverse Reactions

[1]  T. Shiohara,et al.  Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. , 2013, Journal of the American Academy of Dermatology.

[2]  L. Naldi,et al.  Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2013, The Journal of investigative dermatology.

[3]  E. Phillips,et al.  Testing for drug hypersensitivity syndromes. , 2013, The Clinical biochemist. Reviews.

[4]  T. Shiohara,et al.  Human herpesvirus 6 reactivation in drug-induced hypersensitivity syndrome and DRESS validation score. , 2012, The American journal of medicine.

[5]  T. Kakamu,et al.  HLA‐A31 strongly associates with carbamazepine‐induced adverse drug reactions but not with carbamazepine‐induced lymphocyte proliferation in a Japanese population , 2012, The Journal of dermatology.

[6]  S. Mallal,et al.  Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire , 2012, Proceedings of the National Academy of Sciences.

[7]  P. Criado,et al.  Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts. , 2012, Anais brasileiros de dermatologia.

[8]  J. Roujeau,et al.  Drug-induced epidermal necrolysis: Important new piece to end the puzzle. , 2011, The Journal of allergy and clinical immunology.

[9]  A. Dunant,et al.  ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis , 2010, Clinical pharmacology and therapeutics.

[10]  T. Shiohara,et al.  Defective Regulatory T Cells In Patients with Severe Drug Eruptions: Timing of the Dysfunction Is Associated with the Pathological Phenotype and Outcome1 , 2009, The Journal of Immunology.

[11]  Yuan-Tsong Chen,et al.  Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis , 2008, Nature Medicine.

[12]  A. Romano,et al.  Skin tests in the diagnosis of drug hypersensitivity reactions. , 2008, Current pharmaceutical design.

[13]  W. Pichler.  The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors , 2008, The World Allergy Organization journal.

[14]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[15]  J. Chung,et al.  Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. , 2005, The American journal of pathology.

[16]  T. Shiohara,et al.  Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome. , 2005, Toxicology.

[17]  J. Roujeau,et al.  Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors , 2000, Clinical and experimental immunology.

[18]  P. Fournier,et al.  Human T cell priming assay: depletion of peripheral blood lymphocytes in CD25(+) cells improves the in vitro detection of weak allergen-specific T cells. , 2014, Experientia supplementum.

[19]  B. Thiers.  HLA-B*5801 Allele as a Genetic Marker for Severe Cutaneous Adverse Reactions Caused by Allopurinol , 2006 .

[20]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .